Reactive oxygen species in myocardial reperfusion injury: From physiopathology to therapeutic approaches

Current Pharmaceutical Biotechnology

Volumn 13, Issue 1, 2012, Pages 97-114

  Braunersreuther, Vincent ^a   Jaquet, Vincent ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

Antioxidants; Ischemia reperfusion injury; Myocardial infarction; Oxidative stress; Reactive oxygen species; Therapeutic strategies

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ALLOPURINOL; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; BIOLOGICAL MARKER; DEFEROXAMINE; DILTIAZEM; EDERAVONE; FREE RADICAL; GLYCERYL TRINITRATE; NICOTINIC ACID; OXIPURINOL; OXYGEN; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; RECOMBINANT ENZYME; RECOMBINANT SUPEROXIDE DISMUTASE; SELENIUM; SIMVASTATIN; STREPTOKINASE; TRIMETAZIDINE; UNCLASSIFIED DRUG; XANTHINE OXIDASE;

ACUTE HEART INFARCTION; APOPTOSIS; ARTICLE; BLOOD FLOW; CELL ACTIVATION; CELL DAMAGE; CELL INFILTRATION; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DNA MARKER; DRUG EFFICACY; DRUG OVERDOSE; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERURICEMIA; INFLAMMATORY CELL; MOLECULAR MECHANICS; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PARACETAMOL OVERDOSE; PATHOPHYSIOLOGY; PROGNOSIS; REPERFUSION INJURY; TREATMENT OUTCOME;

ANIMALS; ANTIOXIDANTS; BIOLOGICAL MARKERS; HUMANS; MYOCARDIAL REPERFUSION INJURY; OXIDATION-REDUCTION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

ANIMALIA;

EID: 84855849542     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112798868782     Document Type: Article

References (203)

1. Mathers, C.D.; Loncar, D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med., 2006, 3(11), e442.
2. Braunwald, E. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded? Circulation, 1989, 79(2), 441-444.
3. Matsumura, K.; Jeremy, R.W.; Schaper, J.; Becker, L.C. Progression of myocardial necrosis during reperfusion of ischemic myocardium. Circulation, 1998, 97(8), 795-804.
4. Frangogiannis, N.G.; Smith, C.W.; Entman, M.L. The inflammatory response in myocardial infarction. Cardiovasc Res., 2002, 53(1), 31-47.
5. Park, J.L.; Lucchesi, B.R. Mechanisms of myocardial reperfusion injury. Ann. Thorac. Surg., 1999, 68(5), 1905-1912.
6. Kilgore, K.S.; Friedrichs, G.S.; Homeister, J.W.; Lucchesi, B.R. The complement system in myocardial ischaemia/reperfusion injury. Cardiovasc. Res., 1994, 28(4), 437-44.
7. Ferrari, R.; Ceconi, C.; Curello, S.; Guarnieri, C.; Caldarera, C. M.; Albertini, A.; Visioli, O. Oxygen-mediated myocardial damage during ischaemia and reperfusion: role of the cellular defences against oxygen toxicity. J. Mol. Cell Cardiol., 1985, 17(10), 937-945.
8. Grech, E. D.; Dodd, N.J.; Jackson, M.J.; Morrison, W.L.; Faragher, E.B.; Ramsdale, D.R. Evidence for free radical generation after primary percutaneous transluminal coronary angioplasty recanalization in acute myocardial infarction. Am. J. Cardiol., 1996, 77(2), 122-127.
9. Levonen, A.L.; Vahakangas, E.; Koponen, J.K.; Yla-Herttuala, S. Antioxidant gene therapy for cardiovascular disease: current status and future perspectives. Circulation, 2008, 117(16), 2142-50.
10. Nohl, H.; Gille, L.; Staniek, K. Intracellular generation of reactive oxygen species by mitochondria. Biochem. Pharmacol., 2005, 69(5), 719-723.
11. Valko, M.; Morris, H.; Cronin, M.T. Metals, toxicity and oxidative stress. Curr. Med. Chem., 2005, 12(10), 1161-1208.
12. Winterbourn, C.C. Reconciling the chemistry and biology of reactive oxygen species. Nat. Chem. Biol., 2008, 4(5), 278-286.
13. Pastor, N.; Weinstein, H.; Jamison, E.; Brenowitz, M. A detailed interpretation of OH radical footprints in a TBP-DNA complex reveals the role of dynamics in the mechanism of sequence-specific binding. J. Mol. Biol., 2000, 304(1), 55-68.
14. Lopez-Mirabal, H.R.; Winther, J.R. Redox characteristics of the eukaryotic cytosol. Biochim. Biophys. Acta, 2008, 1783(4), 629-640.
15. Aust, S.D.; Morehouse, L.A.; Thomas, C.E. Role of metals in oxygen radical reactions. J. Free Radic. Biol. Med., 1985, 1(1), 3-25.
16. Halliwell, B.; Gutteridge, J.M. Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem. J., 1984, 219(1), 1-14.
17. Stohs, S.J.; Bagchi, D. Oxidative mechanisms in the toxicity of metal ions. Free Radic. Biol. Med., 1995, 18(2), 321-336.
18. Babior, B.M. Phagocytes and oxidative stress. Am. J. Med., 2000, 109(1), 33-44.
19. Malle, E.; Furtmuller, P.G.; Sattler, W.; Obinger, C. Myeloperoxidase: a target for new drug development? Br. J. Pharmacol., 2007, 152(6), 838-854.
20. Nagata, M. Inflammatory cells and oxygen radicals. Curr. Drug Targets Inflamm. Allergy, 2005, 4(4), 503-504.
21. Hultqvist, M.; Olsson, L.M.; Gelderman, K.A.; Holmdahl, R. The protective role of ROS in autoimmune disease. Trends Immunol., 2009, 30(5), 201-208.
22. Schappi, M.G.; Jaquet, V.; Belli, D.C.; Krause, K.H. Hyperinflammation in chronic granulomatous disease and anti inflammatory role of the phagocyte NADPH oxidase. Semin. Immunopathol., 2008, 30(3), 255-271.
23. Bergendi, L.; Benes, L.; Durackova, Z.; Ferencik, M. Chemistry, physiology and pathology of free radicals. Life Sci., 1999, 65(18-19), 1865-1874.
24. Stadtman, E.R.; Berlett, B.S. Reactive oxygen-mediated protein oxidation in aging and disease. Chem. Res. Toxicol., 1997, 10(5), 485-494.
25. Forstermann, U. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat. Clin. Pract. Cardiovasc Med., 2008, 5(6), 338-349.
26. Rinaldi, M.; Moroni, P.; Paape, M.J.; Bannerman, D.D. Evaluation of assays for the measurement of bovine neutrophil reactive oxygen species. Vet. Immunol. Immunopathol., 2007, 115(1-2), 107-125.
27. Dikalov, S.; Griendling, K.K.; Harrison, D.G. Measurement of reactive oxygen species in cardiovascular studies. Hypertension, 2007, 49(4), 717-727.
28. Giustarini, D.; Dalle-Donne, I.; Tsikas, D.; Rossi, R. Oxidative stress and human diseases: Origin, link, measurement, mechanisms, and biomarkers. Crit. Rev. Clin. Lab. Sci., 2009, 46(5-6), 241-281.
29. Marczin, N.; El-Habashi, N.; Hoare, G.S.; Bundy, R.E.; Yacoub, M. Antioxidants in myocardial ischemia-reperfusion injury: therapeutic potential and basic mechanisms. Arch. Biochem. Biophys., 2003, 420(2), 222-236.
30. Blumberg, J. Use of biomarkers of oxidative stress in research studies. J. Nutr., 2004, 134(11), 3188S-3189S.
31. Ikeda, Y.; Matsumoto, K.; Dohi, K.; Jimbo, H.; Sasaki, K.; Satoh, K. Direct superoxide scavenging activity of nonsteroidal antiinflammatory drugs: determination by electron spin resonance using the spin trap method. Headache, 2001, 41(2), 138-141.
32. Quick, K.L.; Ali, S.S.; Arch, R.; Xiong, C.; Wozniak, D.; Dugan, L.L. A carboxyfullerene SOD mimetic improves cognition and extends the lifespan of mice. Neurobiol. Aging., 2008, 29(1), 117-128.
33. Baudry, N.; Laemmel, E.; Vicaut, E. In vivo reactive oxygen species production induced by ischemia in muscle arterioles of mice: involvement of xanthine oxidase and mitochondria. Am. J. Physiol. Heart Circ. Physiol., 2008, 294(2), H821-828.
34. Veglia, F.; Werba, J. P.; Tremoli, E.; Squellerio, I.; Sisillo, E.; Parolari, A.; Minardi, F.; Cavalca, V. Assessment of oxidative stress in coronary artery bypass surgery: comparison between the global index OXY-SCORE and individual biomarkers. Biomarkers, 2009, 14(7), 465-472.
35. Veglia, F.; Cavalca, V.; Tremoli, E. OXY-SCORE: a global index to improve evaluation of oxidative stress by combining pro-and antioxidant markers. Methods Mol. Biol., 2010, 594, 197-213.
36. Veglia, F.; Cighetti, G.; De Franceschi, M.; Zingaro, L.; Boccotti, L.; Tremoli, E.; Cavalca, V. Age-and gender-related oxidative status determined in healthy subjects by means of OXY-SCORE, a potential new comprehensive index. Biomarkers, 2006, 11(6), 562-573.
37. Shite, J.; Qin, F.; Mao, W.; Kawai, H.; Stevens, S.Y.; Liang, C. Antioxidant vitamins attenuate oxidative stress and cardiac dysfunction in tachycardia-induced cardiomyopathy. J. Am. Coll Cardiol., 2001, 38(6), 1734-1740.
38. Haghdoost, S.; Czene, S.; Naslund, I.; Skog, S.; Harms-Ringdahl, M. Extracellular 8-oxo-dG as a sensitive parameter for oxidative stress in vivo and in vitro. Free Radic. Res., 2005, 39(2), 153-162.
39. Cathcart, R.; Schwiers, E.; Saul, R.L.; Ames, B.N. Thymine glycol and thymidine glycol in human and rat urine: a possible assay for oxidative DNA damage. Proc. Natl. Acad Sci. U S A., 1984, 81(18), 5633-5637.
40. Makropoulos, W.; Kocher, K.; Heintz, B.; Schwarz, E.R.; Mertens, P.R.; Stefanidis, I. Urinary thymidine glycol as a biomarker for oxidative stress after kidney transplantation. Ren. Fail., 2000, 22(4), 499-510.
41. Cuong, D.V.; Warda, M.; Kim, N.; Park, W.S.; Ko, J.H.; Kim, E.; Han, J. Dynamic changes in nitric oxide and mitochondrial oxidative stress with site-dependent differential tissue response during anoxic preconditioning in rat heart. Am. J. Physiol. Heart Circ. Physiol., 2007, 293(3), H1457-465.
42. ter Steege, J.C.; Koster-Kamphuis, L.; van Straaten, E.A.; Forget, P.P.; Buurman, W.A. Nitrotyrosine in plasma of celiac disease patients as detected by a new sandwich ELISA. Free Radic. Biol. Med., 1998, 25(8), 953-963.
43. Cordis, G.A.; Maulik, N.; Das, D.K. Detection of oxidative stress in heart by estimating the dinitrophenylhydrazine derivative of malonaldehyde. J. Mol. Cell Cardiol., 1995, 27(8), 1645-1653.
44. Wu, W.; Chen, Y.; d'Avignon, A.; Hazen, S. L. 3-Bromotyrosine and 3,5-dibromotyrosine are major products of protein oxidation by eosinophil peroxidase: potential markers for eosinophil-dependent tissue injury in vivo. Biochemistry, 1999, 38(12), 3538-3548.
45. Hurd, T.R.; Prime, T.A.; Harbour, M. E.; Lilley, K.S.; Murphy, M.P. Detection of reactive oxygen species-sensitive thiol proteins by redox difference gel electrophoresis: implications for mitochondrial redox signaling. J. Biol. Chem., 2007, 282(30), 22040-22051.
46. Templar, J.; Kon, S.P.; Milligan, T.P.; Newman, D.J.; Raftery, M.J. Increased plasma malondialdehyde levels in glomerular disease as determined by a fully validated HPLC method. Nephrol. Dial. Transplant, 1999, 14(4), 946-951.
47. Candan, N.; Tuzmen, N. Very rapid quantification of malondialdehyde (MDA) in rat brain exposed to lead, aluminium and phenolic antioxidants by high-performance liquid chromatographyfluorescence detection. Neurotoxicology, 2008, 29(4), 708-713.
48. Smith, H.M.; Hamblin, M.; Hill, M.F. Greater propensity of diabetic myocardium for oxidative stress after myocardial infarction is associated with the development of heart failure. J. Mol. Cell Cardiol., 2005, 39(4), 657-665.
49. Ekuni, D.; Tomofuji, T.; Sanbe, T.; Irie, K.; Azuma, T.; Maruyama, T.; Tamaki, N.; Murakami, J.; Kokeguchi, S.; Yamamoto, T. Vitamin C intake attenuates the degree of experimental atherosclerosis induced by periodontitis in the rat by decreasing oxidative stress. Arch. Oral. Biol., 2009, 54(5), 495-502.
50. Uchida, K.; Kanematsu, M.; Morimitsu, Y.; Osawa, T.; Noguchi, N.; Niki, E. Acrolein is a product of lipid peroxidation reaction. Formation of free acrolein and its conjugate with lysine residues in oxidized low density lipoproteins. J. Biol. Chem., 1998, 273(26), 16058-16066.
51. Eaton, P.; Li, J.M.; Hearse, D.J.; Shattock, M.J. Formation of 4-hydroxy-2-nonenal-modified proteins in ischemic rat heart. Am. J. Physiol., 1999, 276(3 Pt 2), H935-943.
52. Droge, W. Free radicals in the physiological control of cell function. Physiol. Rev., 2002, 82(1), 47-95.
53. Nathan, C. Specificity of a third kind: reactive oxygen and nitrogen intermediates in cell signaling. J. Clin. Invest., 2003, 111(6), 769-778.
54. Mates, J.M.; Perez-Gomez, C.; Nunez de Castro, I. Antioxidant enzymes and human diseases. Clin. Biochem., 1999, 32(8), 595-603.
55. Tsai, J.C.; Jain, M.; Hsieh, C.M.; Lee, W.S.; Yoshizumi, M.; Patterson, C.; Perrella, M.A.; Cooke, C.; Wang, H.; Haber, E.; Schlegel, R.; Lee, M.E. Induction of apoptosis by pyrrolidinedithiocarbamate and N-acetylcysteine in vascular smooth muscle cells. J. Biol. Chem., 1996, 271(7), 3667-3670.
56. Cox, A.G.; Winterbourn, C.C.; Hampton, M.B. Mitochondrial peroxiredoxin involvement in antioxidant defence and redox signalling. Biochem. J., 425(2), 313-325.
57. Yamawaki, H.; Haendeler, J.; Berk, B.C. Thioredoxin: a key regulator of cardiovascular homeostasis. Circ. Res., 2003, 93(11), 1029-1033.
58. Kang, S.W.; Chae, H.Z.; Seo, M.S.; Kim, K.; Baines, I.C.; Rhee, S.G. Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor-alpha. J. Biol. Chem., 1998, 273(11), 6297-6302.
59. Das, K.C.; Lewis-Molock, Y.; White, C.W. Elevation of manganese superoxide dismutase gene expression by thioredoxin. Am. J. Respir. Cell Mol. Biol., 1997, 17(6), 713-726.
60. Zhang, J.; Li, Y.D.; Patel, J.M.; Block, E.R. Thioredoxin overexpression prevents NO-induced reduction of NO synthase activity in lung endothelial cells. Am. J. Physiol., 1998, 275(2 Pt 1), L288-293.
61. Wu, J.; Hecker, J.G.; Chiamvimonvat, N. Antioxidant enzyme gene transfer for ischemic diseases. Adv. Drug Deliv. Rev., 2009, 61(4), 351-363.
62. Fridovich, I. Superoxide radical and superoxide dismutases. Annu. Rev. Biochem., 1995, 64, 97-112.
63. Davies, K.J.; Delsignore, M.E.; Lin, S.W. Protein damage and degradation by oxygen radicals. II. Modification of amino acids. J. Biol. Chem., 1987, 262(20), 9902-9907.
64. Venardos, K.M.; Perkins, A.; Headrick, J.; Kaye, D.M. Myocardial ischemia-reperfusion injury, antioxidant enzyme systems, and selenium: a review. Curr. Med. Chem., 2007, 14(14), 1539-1549.
65. Buja, L.M.; Hagler, H.K.; Willerson, J.T. Altered calcium homeostasis in the pathogenesis of myocardial ischemic and hypoxic injury. Cell Calcium., 1988, 9(5-6), 205-217.
66. Martindale, J.L.; Holbrook, N.J. Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol., 2002, 192(1), 1-15.
67. Dixon, I.M.; Hata, T.; Dhalla, N.S. Sarcolemmal Na(+)-K(+)-ATPase activity in congestive heart failure due to myocardial infarction. Am. J. Physiol., 1992, 262(3 Pt 1), C664-671.
68. Dhalla, N.S.; Temsah, R.M. Sarcoplasmic reticulum and cardiac oxidative stress: an emerging target for heart disease. Expert. Opin Ther. Targets, 2001, 5(2), 205-217.
69. Dhalla, N.S.; Elmoselhi, A.B.; Hata, T.; Makino, N. Status of myocardial antioxidants in ischemia-reperfusion injury. Cardiovasc. Res., 2000, 47(3), 446-456.
70. Lu, L.; Quinn, M.T.; Sun, Y. Oxidative stress in the infarcted heart: role of de novo angiotensin II production. Biochem. Biophys. Res. Commun., 2004, 325(3), 943-951.
71. Usal, A.; Acarturk, E.; Yuregir, G.T.; Unlukurt, I.; Demirci, C.; Kurt, H. I.; Birand, A. Decreased glutathione levels in acute myocardial infarction. Jpn. Heart J., 1996, 37(2), 177-182.
72. Fukui, T.; Yoshiyama, M.; Hanatani, A.; Omura, T.; Yoshikawa, J.; Abe, Y. Expression of p22-phox and gp91-phox, essential components of NADPH oxidase, increases after myocardial infarction. Biochem. Biophys. Res. Commun, 2001, 281(5), 1200-1206.
73. Garcia-Dorado, D.; Piper, H.M. Postconditioning: reperfusion of "reperfusion injury" after hibernation. Cardiovasc. Res., 2006, 69(1), 1-3.
74. Braunersreuther, V.; Pellieux, C.; Pelli, G.; Burger, F.; Steffens, S.; Montessuit, C.; Weber, C.; Proudfoot, A.; Mach, F.; Arnaud, C. Chemokine CCL5/RANTES inhibition reduces myocardial reperfusion injury in atherosclerotic mice. J. Mol. Cell Cardiol., 2009.
75. Hayward, R.; Campbell, B.; Shin, Y.K.; Scalia, R.; Lefer, A.M. Recombinant soluble P-selectin glycoprotein ligand-1 protects against myocardial ischemic reperfusion injury in cats. Cardiovasc Res., 1999, 41(1), 65-76.
76. Zweier, J.L.; Kuppusamy, P.; Williams, R.; Rayburn, B.K.; Smith, D.; Weisfeldt, M.L.; Flaherty, J.T. Measurement and characterization of postischemic free radical generation in the isolated perfused heart. J. Biol. Chem., 1989, 264(32), 18890-18895.
77. Henry, T.D.; Archer, S.L.; Nelson, D.; Weir, E.K.; From, A.H. Enhanced chemiluminescence as a measure of oxygen-derived free radical generation during ischemia and reperfusion. Circ. Res., 1990, 67(6), 1453-61.
78. Zweier, J.L.; Flaherty, J.T.; Weisfeldt, M.L. Direct measurement of free radical generation following reperfusion of ischemic myocardium. Proc. Natl. Acad. Sci. U S A., 1987, 84(5), 1404-1407.
79. Ambrosio, G.; Zweier, J.L.; Flaherty, J.T. The relationship between oxygen radical generation and impairment of myocardial energy metabolism following post-ischemic reperfusion. J. Mol. Cell Cardiol., 1991, 23(12), 1359-1374.
80. Zweier, J.L.; Talukder, M.A. The role of oxidants and free radicals in reperfusion injury. Cardiovasc. Res., 2006, 70(2), 181-190.
81. Lesnefsky, E.J.; Tandler, B.; Ye, J.; Slabe, T.J.; Turkaly, J.; Hoppel, C.L. Myocardial ischemia decreases oxidative phosphorylation through cytochrome oxidase in subsarcolemmal mitochondria. Am. J. Physiol., 1997, 273(3 Pt 2), H1544-1554.
82. Vanden Hoek, T.L.; Shao, Z.; Li, C.; Schumacker, P.T.; Becker, L.B. Mitochondrial electron transport can become a significant source of oxidative injury in cardiomyocytes. J. Mol. Cell Cardiol., 1997, 29(9), 2441-2450.
83. Murphy, E.; Steenbergen, C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol. Rev., 2008, 88(2), 581-609.
84. Di Lisa, F.; Menabo, R.; Canton, M.; Barile, M.; Bernardi, P. Opening of the mitochondrial permeability transition pore causes depletion of mitochondrial and cytosolic NAD+ and is a causative event in the death of myocytes in postischemic reperfusion of the heart. J. Biol. Chem., 2001, 276(4), 2571-2575.
85. Griffiths, E.J.; Halestrap, A.P. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem. J., 1995, 307(Pt 1), 93-98.
86. Juhaszova, M.; Zorov, D.B.; Kim, S.H.; Pepe, S.; Fu, Q.; Fishbein, K.W.; Ziman, B.D.; Wang, S.; Ytrehus, K.; Antos, C.L.; Olson, E.N.; Sollott, S.J. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J. Clin. Invest., 2004, 113(11), 1535-1549.
87. Piot, C.; Croisille, P.; Staat, P.; Thibault, H.; Rioufol, G.; Mewton, N.; Elbelghiti, R.; Cung, T.T.; Bonnefoy, E.; Angoulvant, D.; Macia, C.; Raczka, F.; Sportouch, C.; Gahide, G.; Finet, G.; Andre-Fouet, X.; Revel, D.; Kirkorian, G.; Monassier, J.P.; Derumeaux, G.; Ovize, M. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N. Engl. J. Med., 2008, 359(5), 473-481.
88. Akgur, F.M.; Brown, M.F.; Zibari, G.B.; McDonald, J.C.; Epstein, C.J.; Ross, C.R.; Granger, D.N. Role of superoxide in hemorrhagic shock-induced P-selectin expression. Am. J. Physiol. Heart Circ. Physiol., 2000, 279(2), H791-797.
89. Shingu, M.; Nobunaga, M. Chemotactic activity generated in human serum from the fifth component of complement by hydrogen peroxide. Am. J. Pathol., 1984, 117(2), 201-206.
90. Sellak, H.; Franzini, E.; Hakim, J.; Pasquier, C. Reactive oxygen species rapidly increase endothelial ICAM-1 ability to bind neutrophils without detectable upregulation. Blood, 1994, 83(9), 2669-2677.
91. Schreck, R.; Rieber, P.; Baeuerle, P.A. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO, J., 1991, 10(8), 2247-2258.
92. Ghosh, S.; May, M.J.; Kopp, E.B. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol., 1998, 16, 225-260.
93. Romson, J.L.; Hook, B.G.; Kunkel, S.L.; Abrams, G.D.; Schork, M.A.; Lucchesi, B.R. Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog. Circulation, 1983, 67(5), 1016-23.
94. Buerke, M.; Weyrich, A.S.; Murohara, T.; Queen, C.; Klingbeil, C.K.; Co, M.S.; Lefer, A.M. Humanized monoclonal antibody DREG-200 directed against I-selectin protects in feline myocardial reperfusion injury. J. Pharmacol. Exp. Ther., 1994, 271(1), 134-142.
95. Fabiani, J.N.; Farah, B.; Vuilleminot, A.; Lecompte, T.; Emerit, I.; Chardigny, C.; Carpentier, A. Chromosomal aberrations and neutrophil activation induced by reperfusion in the ischaemic human heart. Eur. Heart J., 1993, 14 Suppl G, 12-7.
96. Steffens, S.; Montecucco, F.; Mach, F. The inflammatory response as a target to reduce myocardial ischaemia and reperfusion injury. Thromb. Haemost., 2009, 102(2), 240-247.
97. Stirpe, F.; Della Corte, E. The regulation of rat liver xanthine oxidase. Conversion in vitro of the enzyme activity from dehydrogenase (type D) to oxidase (type O). J. Biol. Chem., 1969, 244(14), 3855-3863.
98. Zweier, J. L.; Broderick, R.; Kuppusamy, P.; Thompson-Gorman, S.; Lutty, G.A. Determination of the mechanism of free radical generation in human aortic endothelial cells exposed to anoxia and reoxygenation. J. Biol. Chem., 1994, 269(39), 24156-24162.
99. Downey, J.M.; Miura, T.; Eddy, L.J.; Chambers, D.E.; Mellert, T.; Hearse, D.J.; Yellon, D.M. Xanthine oxidase is not a source of free radicals in the ischemic rabbit heart. J. Mol. Cell Cardiol., 1987, 19(11), 1053-1060.
100. Eddy, L.J.; Stewart, J.R.; Jones, H.P.; Engerson, T.D.; McCord, J.M.; Downey, J.M. Free radical-producing enzyme, xanthine oxidase, is undetectable in human hearts. Am. J. Physiol., 1987, 253(3 Pt 2), H709-711.
101. de Jong, J.W.; van der Meer, P.; Nieukoop, A.S.; Huizer, T.; Stroeve, R.J.; Bos, E. Xanthine oxidoreductase activity in perfused hearts of various species, including humans. Circ. Res., 1990, 67(3), 770-773.
102. Houston, M.; Estevez, A.; Chumley, P.; Aslan, M.; Marklund, S.; Parks, D.A.; Freeman, B.A. Binding of xanthine oxidase to vascular endothelium. Kinetic characterization and oxidative impairment of nitric oxide-dependent signaling. J. Biol. Chem., 1999, 274(8), 4985-4994.
103. Parks, D.A.; Granger, D.N. Ischemia-induced vascular changes: role of xanthine oxidase and hydroxyl radicals. Am. J. Physiol., 1983, 245(2), G285-289.
104. Granger, D.N. Role of xanthine oxidase and granulocytes in ischemia-reperfusion injury. Am. J. Physiol., 1988, 255(6 Pt 2), H1269-275.
105. Granger, D.N.; Rutili, G.; McCord, J.M. Superoxide radicals in feline intestinal ischemia. Gastroenterology, 1981, 81(1), 22-29.
106. Zweier, J.L. Measurement of superoxide-derived free radicals in the reperfused heart. Evidence for a free radical mechanism of reperfusion injury. J. Biol. Chem., 1988, 263(3), 1353-1357.
107. Wang, P.; Zweier, J.L. Measurement of nitric oxide and peroxynitrite generation in the postischemic heart. Evidence for peroxynitrite-mediated reperfusion injury. J. Biol. Chem., 1996, 271(46), 29223-29230.
108. Thompson-Gorman, S.L.; Zweier, J.L. Evaluation of the role of xanthine oxidase in myocardial reperfusion injury. J. Biol. Chem., 1990, 265(12), 6656-6663.
109. Bergsland, J.; Lobalsamo, L.; Lajos, P.S.; Feldman, M.J.; Vanwylen, D.G. Oxypurinol protects normothermic ischemic hearts. J. Card. Surg., 1990, 5(4), 347-353.
110. Brown, J.M.; Terada, L.S.; Grosso, M.A.; Whitmann, G.J.; Velasco, S.E.; Patt, A.; Harken, A.H.; Repine, J.E. Xanthine oxidase produces hydrogen peroxide which contributes to reperfusion injury of ischemic, isolated, perfused rat hearts. J. Clin. Invest., 1988, 81(4), 1297-1301.
111. Terada, L.S.; Rubinstein, J.D.; Lesnefsky, E.J.; Horwitz, L.D.; Leff, J.A.; Repine, J.E. Existence and participation of xanthine oxidase in reperfusion injury of ischemic rabbit myocardium. Am. J. Physiol., 1991, 260(3 Pt 2), H805-810.
112. Castelli, P.; Condemi, A.M.; Brambillasca, C.; Fundaro, P.; Botta, M.; Lemma, M.; Vanelli, P.; Santoli, C.; Gatti, S.; Riva, E. Improvement of cardiac function by allopurinol in patients undergoing cardiac surgery. J. Cardiovasc Pharmacol., 1995, 25(1), 119-125.
113. Guan, W.; Osanai, T.; Kamada, T.; Hanada, H.; Ishizaka, H.; Onodera, H.; Iwasa, A.; Fujita, N.; Kudo, S.; Ohkubo, T.; Okumura, K. Effect of allopurinol pretreatment on free radical generation after primary coronary angioplasty for acute myocardial infarction. J. Cardiovasc. Pharmacol., 2003, 41(5), 699-705.
114. Yamazaki, I.; Soma, T.; Ichikawa, Y.; Iwai, Y.; Kondo, J.; Matsumoto, A. [Usefulness of allopurinol for prevention of myocardial reperfusion injury in open heart surgery]. Nippon Kyobu Geka Gakkai Zasshi, 1995, 43(1), 26-31.
115. Coetzee, A.; Roussouw, G.; Macgregor, L. Failure of allopurinol to improve left ventricular stroke work after cardiopulmonary bypass surgery. J. Cardiothorac Vasc. Anesth., 1996, 10(5), 627-633.
116. Taggart, D.P.; Young, V.; Hooper, J.; Kemp, M.; Walesby, R.; Magee, P.; Wright, J.E. Lack of cardioprotective efficacy of allopurinol in coronary artery surgery. Br. Heart J., 1994, 71(2), 177-181.
117. Bedard, K.; Krause, K.H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev., 2007, 87(1), 245-313.
118. Babior, B.M.; Lambeth, J.D.; Nauseef, W. The neutrophil NADPH oxidase. Arch. Biochem. Biophys., 2002, 397(2), 342-344.
119. Herkert, O.; Diebold, I.; Brandes, R.P.; Hess, J.; Busse, R.; Gorlach, A. NADPH oxidase mediates tissue factor-dependent surface procoagulant activity by thrombin in human vascular smooth muscle cells. Circulation, 2002, 105(17), 2030-2036.
120. Bayraktutan, U.; Blayney, L.; Shah, A.M. Molecular characterization and localization of the NAD(P)H oxidase components gp91-phox and p22-phox in endothelial cells. Arterioscler Thromb. Vasc. Biol., 2000, 20(8), 1903-1911.
121. Gorlach, A.; Brandes, R.P.; Nguyen, K.; Amidi, M.; Dehghani, F.; Busse, R. A gp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circ. Res., 2000, 87(1), 26-32.
122. Chamseddine, A.H.; Miller, F.J., Jr. Gp91phox contributes to NADPH oxidase activity in aortic fibroblasts but not smooth muscle cells. Am. J. Physiol. Heart Circ. Physiol., 2003, 285(6), H2284-2289.
123. Pagano, P.J.; Clark, J.K.; Cifuentes-Pagano, M.E.; Clark, S.M.; Callis, G.M.; Quinn, M.T. Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. Proc. Natl. Acad. Sci. U S A., 1997, 94(26), 14483-14488.
124. Krijnen, P.A.; Meischl, C.; Hack, C.E.; Meijer, C.J.; Visser, C.A.; Roos, D.; Niessen, H.W. Increased Nox2 expression in human cardiomyocytes after acute myocardial infarction. J. Clin. Pathol., 2003, 56(3), 194-199.
125. Xiao, L.; Pimentel, D.R.; Wang, J.; Singh, K.; Colucci, W.S.; Sawyer, D.B. Role of reactive oxygen species and NAD(P)H oxidase in alpha(1)-adrenoceptor signaling in adult rat cardiac myocytes. Am. J. Physiol. Cell Physiol., 2002, 282(4), C926-934.
126. Zalba, G.; San Jose, G.; Moreno, M.U.; Fortuno, M.A.; Fortuno, A.; Beaumont, F.J.; Diez, J. Oxidative stress in arterial hypertension: role of NAD(P)H oxidase. Hypertension, 2001, 38 (6), 1395-1399.
127. Liu, J.; Yang, F.; Yang, X.P.; Jankowski, M.; Pagano, P.J. NAD(P)H oxidase mediates angiotensin II-induced vascular macrophage infiltration and medial hypertrophy. Arterioscler Thromb. Vasc. Biol., 2003, 23(5), 776-782.
128. Hoffmeyer, M.R.; Jones, S.P.; Ross, C.R.; Sharp, B.; Grisham, M.B.; Laroux, F.S.; Stalker, T.J.; Scalia, R.; Lefer, D.J. Myocardial ischemia/reperfusion injury in NADPH oxidase-deficient mice. Circ. Res., 2000, 87(9), 812-817.
129. Frantz, S.; Brandes, R.P.; Hu, K.; Rammelt, K.; Wolf, J.; Scheuermann, H.; Ertl, G.; Bauersachs, J. Left ventricular remodeling after myocardial infarction in mice with targeted deletion of the NADPH oxidase subunit gp91PHOX. Basic. Res. Cardiol., 2006, 101(2), 127-132.
130. Zhao, W.; Zhao, D.; Yan, R.; Sun, Y. Cardiac oxidative stress and remodeling following infarction: role of NADPH oxidase. Cardiovasc Pathol., 2008.
131. Doerries, C.; Grote, K.; Hilfiker-Kleiner, D.; Luchtefeld, M.; Schaefer, A.; Holland, S. M.; Sorrentino, S.; Manes, C.; Schieffer, B.; Drexler, H.; Landmesser, U. Critical role of the NAD(P)H oxidase subunit p47phox for left ventricular remodeling/dysfunction and survival after myocardial infarction. Circ. Res., 2007, 100(6), 894-903.
132. Looi, Y.H.; Grieve, D.J.; Siva, A.; Walker, S.J.; Anilkumar, N.; Cave, A.C.; Marber, M.; Monaghan, M.J.; Shah, A.M. Involvement of Nox2 NADPH oxidase in adverse cardiac remodeling after myocardial infarction. Hypertension, 2008, 51(2), 319-325.
133. Qin, F.; Simeone, M.; Patel, R. Inhibition of NADPH oxidase reduces myocardial oxidative stress and apoptosis and improves cardiac function in heart failure after myocardial infarction. Free Radic. Biol. Med., 2007, 43(2), 271-281.
134. Forstermann, U.; Closs, E.I.; Pollock, J.S.; Nakane, M.; Schwarz, P.; Gath, I.; Kleinert, H. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension, 1994, 23(6 Pt 2), 1121-1131.
135. Liu, P.; Hock, C.E.; Nagele, R.; Wong, P.Y. Formation of nitric oxide, superoxide, and peroxynitrite in myocardial ischemiareperfusion injury in rats. Am. J. Physiol., 1997, 272(5 Pt 2), H2327-2336.
136. Ungureanu-Longrois, D.; Balligand, J.L.; Kelly, R.A.; Smith, T.W. Myocardial contractile dysfunction in the systemic inflammatory response syndrome: role of a cytokine-inducible nitric oxide synthase in cardiac myocytes. J. Mol. Cell Cardiol., 1995, 27(1), 155-167.
137. Balligand, J.L.; Ungureanu-Longrois, D.; Simmons, W.W.; Pimental, D.; Malinski, T.A.; Kapturczak, M.; Taha, Z.; Lowenstein, C.J.; Davidoff, A.J.; Kelly, R.A. Cytokine-inducible nitric oxide synthase (iNOS) expression in cardiac myocytes. Characterization and regulation of iNOS expression and detection of iNOS activity in single cardiac myocytes in vitro. J. Biol. Chem., 1994, 269(44), 27580-27588.
138. Vasquez-Vivar, J.; Kalyanaraman, B.; Martasek, P.; Hogg, N.; Masters, B.S.; Karoui, H.; Tordo, P.; Pritchard, K.A., Jr. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc. Natl. Acad. Sci. U S A., 1998, 95(16), 9220-9225.
139. Yamashiro, S.; Noguchi, K.; Matsuzaki, T.; Miyagi, K.; Nakasone, J.; Sakanashi, M.; Koja, K. Beneficial effect of tetrahydrobiopterin on ischemia-reperfusion injury in isolated perfused rat hearts. J. Thorac. Cardiovasc Surg., 2002, 124(4), 775-784.
140. Verma, S.; Maitland, A.; Weisel, R.D.; Fedak, P.W.; Pomroy, N.C.; Li, S.H.; Mickle, D.A.; Li, R.K.; Rao, V. Novel cardioprotective effects of tetrahydrobiopterin after anoxia and reoxygenation: Identifying cellular targets for pharmacologic manipulation. J. Thorac. Cardiovasc. Surg., 2002, 123(6), 1074-1083.
141. Wattanapitayakul, S.K.; Weinstein, D.M.; Holycross, B.J.; Bauer, J.A. Endothelial dysfunction and peroxynitrite formation are early events in angiotensin-induced cardiovascular disorders. Faseb. J., 2000, 14(2), 271-278.
142. Bauersachs, J.; Bouloumie, A.; Fraccarollo, D.; Hu, K.; Busse, R.; Ertl, G. Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression: role of enhanced vascular superoxide production. Circulation, 1999, 100(3), 292-298.
143. Kooy, N.W.; Lewis, S.J.; Royall, J.A.; Ye, Y.Z.; Kelly, D.R.; Beckman, J.S. Extensive tyrosine nitration in human myocardial inflammation: evidence for the presence of peroxynitrite. Crit. Care Med., 1997, 25(5), 812-819.
144. Buttery, L.D.; Springall, D.R.; Chester, A.H.; Evans, T.J.; Standfield, E.N.; Parums, D.V.; Yacoub, M.H.; Polak, J.M. Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Lab. Invest., 1996, 75(1), 77-85.
145. Lefer, D. J.; Scalia, R.; Campbell, B.; Nossuli, T.; Hayward, R.; Salamon, M.; Grayson, J.; Lefer, A.M. Peroxynitrite inhibits leukocyte-endothelial cell interactions and protects against ischemiareperfusion injury in rats. J. Clin. Invest., 1997, 99(4), 684-691.
146. Nossuli, T.O.; Hayward, R.; Jensen, D.; Scalia, R.; Lefer, A.M. Mechanisms of cardioprotection by peroxynitrite in myocardial ischemia and reperfusion injury. Am. J. Physiol., 1998, 275(2 Pt 2), H509-519.
147. Ferdinandy, P.; Schulz, R. Peroxynitrite: toxic or protective in the heart? Circ. Res., 2001, 88(2), E12-13.
148. Lalu, M.M.; Wang, W.; Schulz, R. Peroxynitrite in myocardial ischemia-reperfusion injury. Heart Fail Rev., 2002, 7(4), 359-369.
149. Ronson, R.S.; Nakamura, M.; Vinten-Johansen, J. The cardiovascular effects and implications of peroxynitrite. Cardiovasc. Res., 1999, 44(1), 47-59.
150. Abramov, A.Y.; Scorziello, A.; Duchen, M.R. Three distinct mechanisms generate oxygen free radicals in neurons and contribute to cell death during anoxia and reoxygenation. J. Neurosci., 2007, 27(5), 1129-1138.
151. Bolli, R.; Becker, L.; Gross, G.; Mentzer, R., Jr.; Balshaw, D.; Lathrop, D.A. Myocardial protection at a crossroads: the need for translation into clinical therapy. Circ. Res., 2004, 95(2), 125-134.
152. Stephens, N.G.; Parsons, A.; Schofield, P.M.; Kelly, F.; Cheeseman, K.; Mitchinson, M.J. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet, 1996, 347(9004), 781-786.
153. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSIPrevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet, 1999, 354(9177), 447-455.
154. Boaz, M.; Smetana, S.; Weinstein, T.; Matas, Z.; Gafter, U.; Iaina, A.; Knecht, A.; Weissgarten, Y.; Brunner, D.; Fainaru, M.; Green, M.S. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebocontrolled trial. Lancet, 2000, 356(9237), 1213-1218.
155. de Gaetano, G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet, 2001, 357(9250), 89-95.
156. Brown, B.G.; Zhao, X.Q.; Chait, A.; Fisher, L.D.; Cheung, M.C.; Morse, J.S.; Dowdy, A.A.; Marino, E.K.; Bolson, E.L.; Alaupovic, P.; Frohlich, J.; Albers, J.J. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med., 2001, 345(22), 1583-1592.
157. Ferrari, R.; Ceconi, C.; Curello, S.; Cargnoni, A.; Alfieri, O.; Pardini, A.; Marzollo, P.; Visioli, O. Oxygen free radicals and myocardial damage: protective role of thiol-containing agents. Am. J. Med., 1991, 91(3C), 95S-105S.
158. Arstall, M.A.; Yang, J.; Stafford, I.; Betts, W.H.; Horowitz, J.D. Nacetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction. Safety and biochemical effects. Circulation, 1995, 92(10), 2855-2862.
159. Sochman, J.; Vrbska, J.; Musilova, B.; Rocek, M. Infarct Size Limitation: acute N-acetylcysteine defense (ISLAND trial): preliminary analysis and report after the first 30 patients. Clin. Cardiol., 1996, 19(2), 94-100.
160. Orhan, G.; Yapici, N.; Yuksel, M.; Sargin, M.; Senay, S.; Yalcin, A.S.; Aykac, Z.; Aka, S.A. Effects of N-acetylcysteine on myocardial ischemia-reperfusion injury in bypass surgery. Heart Vessels, 2006, 21(1), 42-47.
161. Yesilbursa, D.; Serdar, A.; Senturk, T.; Serdar, Z.; Sag, S.; Cordan, J. Effect of N-acetylcysteine on oxidative stress and ventricular function in patients with myocardial infarction. Heart Vessels, 2006, 21(1), 33-37.
162. Prabhu, A.; Sujatha, D.I.; Kanagarajan, N.; Vijayalakshmi, M.A.; Ninan, B. Effect of N-Acetylcysteine in Attenuating Ischemic Reperfusion Injury in Patients Undergoing Coronary Artery Bypass Grafting with Cardiopulmonary Bypass. Ann. Vasc. Surg., 2009.
163. El-Hamamsy, I.; Stevens, L.M.; Carrier, M.; Pellerin, M.; Bouchard, D.; Demers, P.; Cartier, R.; Page, P.; Perrault, L.P. Effect of intravenous N-acetylcysteine on outcomes after coronary artery bypass surgery: a randomized, double-blind, placebocontrolled clinical trial. J. Thorac. Cardiovasc. Surg., 2007, 133(1), 7-12.
164. Peker, O.; Peker, T.; Erdogan, D.; Ozaydin, M.; Kapan, S.; Sutcu, R.; Ibrisim, E. Effects of intravenous N-acetylcysteine on periprocedural myocardial injury after on-pump coronary artery by-pass grafting. J Cardiovasc Surg. (Torino), 2008, 49(4), 527-531.
165. Koksal, H.; Rahman, A.; Burma, O.; Halifeoglu, I.; Bayar, M.K. The effects of low dose N-acetylcysteine (NAC) as an adjunct to cardioplegia in coronary artery bypass surgery. Anadolu Kardiyol Derg., 2008, 8(6), 437-443.
166. Johnson, W.D.; Kayser, K.L.; Brenowitz, J.B.; Saedi, S.F. A randomized controlled trial of allopurinol in coronary bypass surgery. Am. Heart J., 1991, 121(1 Pt 1), 20-24.
167. Rashid, M.A.; William-Olsson, G. Influence of allopurinol on cardiac complications in open heart operations. Ann. Thorac. Surg., 1991, 52(1), 127-130.
168. Coghlan, J.G.; Flitter, W.D.; Clutton, S.M.; Panda, R.; Daly, R.; Wright, G.; Ilsley, C.D.; Slater, T.F. Allopurinol pretreatment improves postoperative recovery and reduces lipid peroxidation in patients undergoing coronary artery bypass grafting. J. Thorac. Cardiovasc. Surg., 1994, 107(1), 248-256.
169. Sisto, T.; Paajanen, H.; Metsa-Ketela, T.; Harmoinen, A.; Nordback, I.; Tarkka, M. Pretreatment with antioxidants and allopurinol diminishes cardiac onset events in coronary artery bypass grafting. Ann. Thorac. Surg., 1995, 59(6), 1519-1523.
170. Parmley, L.F.; Mufti, A.G.; Downey, J.M. Allopurinol therapy of ischemic heart disease with infarct extension. Can. J. Cardiol., 1992, 8(3), 280-286.
171. Yau, T. M.; Weisel, R.D.; Mickle, D.A.; Burton, G.W.; Ingold, K.U.; Ivanov, J.; Mohabeer, M.K.; Tumiati, L.; Carson, S. Vitamin E for coronary bypass operations. A prospective, double-blind, randomized trial. J. Thorac. Cardiovasc. Surg., 1994, 108(2), 302-310.
172. Dingchao, H.; Zhiduan, Q.; Liye, H.; Xiaodong, F. The protective effects of high-dose ascorbic acid on myocardium against reperfusion injury during and after cardiopulmonary bypass. Thorac. Cardiovasc. Surg., 1994, 42(5), 276-278.
173. Demirag, K.; Askar, F.Z.; Uyar, M.; Cevik, A.; Ozmen, D.; Mutaf, I.; Bayindir, O. The protective effects of high dose ascorbic acid and diltiazem on myocardial ischaemia-reperfusion injury. Middle East J. Anesthesiol., 2001, 16(1), 67-79.
174. Westhuyzen, J.; Cochrane, A.D.; Tesar, P.J.; Mau, T.; Cross, D.B.; Frenneaux, M.P.; Khafagi, F.A.; Fleming, S.J. Effect of preoperative supplementation with alpha-tocopherol and ascorbic acid on myocardial injury in patients undergoing cardiac operations. J. Thorac. Cardiovasc. Surg., 1997, 113(5), 942-948.
175. Lassnigg, A.; Punz, A.; Barker, R.; Keznickl, P.; Manhart, N.; Roth, E.; Hiesmayr, M. Influence of intravenous vitamin E supplementation in cardiac surgery on oxidative stress: a doubleblinded, randomized, controlled study. Br. J. Anaesth., 2003, 90(2), 148-154.
176. Liu, D.; Liu, S.; Huang, Y.; Liu, Y.; Zhang, Z.; Han, L. Effect of selenium on human myocardial glutathione peroxidase gene expression. Chin. Med. J. (Engl.), 2000, 113(9), 771-775.
177. Paraskevaidis, I.A.; Iliodromitis, E.K.; Vlahakos, D.; Tsiapras, D.P.; Nikolaidis, A.; Marathias, A.; Michalis, A.; Kremastinos, D.T. Deferoxamine infusion during coronary artery bypass grafting ameliorates lipid peroxidation and protects the myocardium against reperfusion injury: immediate and long-term significance. Eur. Heart J., 2005, 26(3), 263-270.
178. Tsujita, K.; Shimomura, H.; Kaikita, K.; Kawano, H.; Hokamaki, J.; Nagayoshi, Y.; Yamashita, T.; Fukuda, M.; Nakamura, Y.; Sa kamoto, T.; Yoshimura, M.; Ogawa, H. Long-term efficacy of edaravone in patients with acute myocardial infarction. Circ. J., 2006, 70(7), 832-837.
179. Flaherty, J.T.; Pitt, B.; Gruber, J.W.; Heuser, R.R.; Rothbaum, D.A.; Burwell, L.R.; George, B.S.; Kereiakes, D.J.; Deitchman, D.; Gustafson, N. Recombinant human superoxide dismutase (h-SOD) fails to improve recovery of ventricular function in patients undergoing coronary angioplasty for acute myocardial infarction. Circulation, 1994, 89(5), 1982-1991.
180. Effect of 48-h intravenous trimetazidine on short-and long-term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy; A double-blind, placebo-controlled, randomized trial. The EMIP-FR Group. European Myocardial Infarction Project--Free Radicals. Eur. Heart J., 2000, 21(18), 1537-1546.
181. De Vries, N.; De Flora, S. N-acetyl-l-cysteine. J. Cell Biochem. Suppl., 1993, 17F, 270-277.
182. Sochman, J.; Kolc, J.; Vrana, M.; Fabian, J. Cardioprotective effects of N-acetylcysteine: the reduction in the extent of infarction and occurrence of reperfusion arrhythmias in the dog. Int. J. Cardiol., 1990, 28(2), 191-196.
183. Alberola, A.; Such, L.; Gil, F.; Zaragoza, R.; Morcillo, E.J. Protective effect of N-acetylcysteine on ischaemia-induced myocardial damage in canine heart. Naunyn Schmiedebergs Arch. Pharmacol., 1991, 343(5), 505-510.
184. Sochman, J. N-acetylcysteine in acute cardiology: 10 years later: what do we know and what would we like to know? J. Am. Coll Cardiol., 2002, 39(9), 1422-1428.
185. Pacher, P.; Nivorozhkin, A.; Szabo, C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol. Rev., 2006, 58(1), 87-114.
186. Southard, J.H.; Belzer, F.O. Organ preservation. Annu. Rev. Med., 1995, 46, 235-247.
187. George, J.; Carr, E.; Davies, J.; Belch, J.J.; Struthers, A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation, 2006, 114(23), 2508-2516.
188. Venardos, K.; Harrison, G.; Headrick, J.; Perkins, A. Selenium supplementation and ischemia-reperfusion injury in rats. Redox. Rep., 2004, 9(6), 317-320.
189. Venardos, K.; Harrison, G.; Headrick, J.; Perkins, A. Effects of dietary selenium on glutathione peroxidase and thioredoxin reductase activity and recovery from cardiac ischemia-reperfusion. J. Trace Elem. Med. Biol., 2004, 18(1), 81-88.
190. Poltronieri, R.; Cevese, A.; Sbarbati, A. Protective effect of selenium in cardiac ischemia and reperfusion. Cardioscience, 1992, 3(3), 155-160.
191. Sellke, F.W.; Shafique, T.; Ely, D.L.; Weintraub, R.M. Coronary endothelial injury after cardiopulmonary bypass and ischemic cardioplegia is mediated by oxygen-derived free radicals. Circulation, 1993, 88(5 Pt 2), II395-400.
192. Stamler, A.; Wang, S.Y.; Aguirre, D.E.; Johnson, R.G.; Sellke, F.W. Cardiopulmonary bypass alters vasomotor regulation of the skeletal muscle microcirculation. Ann. Thorac. Surg., 1997, 64(2), 460-465.
193. Menasche, P.; Antebi, H.; Alcindor, L.G.; Teiger, E.; Perez, G.; Giudicelli, Y.; Nordmann, R.; Piwnica, A. Iron chelation by deferoxamine inhibits lipid peroxidation during cardiopulmonary bypass in humans. Circulation, 1990, 82(5 Suppl.), IV390-396.
194. Ferreira, R.; Burgos, M.; Milei, J.; Llesuy, S.; Molteni, L.; Hourquebie, H.; Boveris, A. Effect of supplementing cardioplegic solution with deferoxamine on reperfused human myocardium. J. Thorac. Cardiovasc. Surg., 1990, 100(5), 708-714.
195. Maridonneau-Parini, I.; Harpey, C. Effect of trimetazidine on membrane damage induced by oxygen free radicals in human red cells. Br. J. Clin. Pharmacol., 1985, 20(2), 148-151.
196. Aubert, A.; Bernard, C.; Clauser, P.; Harpey, C.; Vaudry, H. Effect of phenazine methosulfate on electrophysiological activity of the semicircular canal: antioxidant properties of trimetazidine. Eur. J. Pharmacol., 1989, 174(2-3), 215-225.
197. Rahman, F.; Toshima, Y.; Kohno, H.; Kinoshita, K.; Tokunaga, K. The protective effects of trimetazidine on normothermic ischemic myocardium in rats. Jpn. J. Surg., 1989, 19(3), 346-350.
198. Rock, C.L. Multivitamin-multimineral supplements: who uses them? Am. J. Clin. Nutr., 2007, 85 (1), 277S-279S.
199. van het Hof, K.H.; Brouwer, I.A.; West, C.E.; Haddeman, E.; Steegers-Theunissen, R.P.; van Dusseldorp, M.; Weststrate, J.A.; Eskes, T.K.; Hautvast, J.G. Bioavailability of lutein from vegetables is 5 times higher than that of beta-carotene. Am. J. Clin. Nutr., 1999, 70(2), 261-268.
200. Kushi, L.H.; Folsom, A.R.; Prineas, R.J.; Mink, P.J.; Wu, Y.; Bostick, R.M. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N. Engl. J. Med., 1996, 334(18), 1156-1562.
201. Haramaki, N.; Stewart, D.B.; Aggarwal, S.; Ikeda, H.; Reznick, A.Z.; Packer, L. Networking antioxidants in the isolated rat heart are selectively depleted by ischemia-reperfusion. Free Radic. Biol. Med., 1998, 25(3), 329-339.
202. Rietjens, I.M. C.M.; Boersma, M.G.; de Haan, L.; Spenkelink, B.; Awad, H.M.; Cnubben, N.H.P.; van Zanden, J.J.; van der Woude, H.; Alink, G.M.; Koeman, J.H. The pro-oxidant chemistry of natural antioxidants vitamin C, vitamin E, carotenoids and flavonoids. Environ. Toxicol. PharmacoL., 2002, 11, 321-333.
203. Bast, A.; Haenen, G.R. The toxicity of antioxidants and their metabolites. Environ. Toxicol. Pharmacol., 2002, 11, 251-258.